We propose to decrease the morbidity and mortality associated with severe aplastic anemia by continuing the evaluation of treatment by marrow grafting using HLA-identical family members as marrow donors. We hope to define the ultimate role of this approach and compare short- and long- term results to those obtained with unrelated marrow grafts and to results without marrow transplantation, Studies will address the problems of graft rejection, acute and chronic graft-versus-host disease (GVHD), infectious complications, and long-term sequelae. We will also continue exploring the usefulness of allogeneic marrow transplantation for the treatment of various genetically determined hematologic disorders including sickle cell anemia.
Showing the most recent 10 out of 788 publications